Alternative splicing at neuroligin site A regulates glycan interaction and synaptogenic activity
Abstract
Post-transcriptional mechanisms regulating cell surface synaptic organizing complexes that control the properties of connections in brain circuits are poorly understood. Alternative splicing regulates the prototypical synaptic organizing complex, neuroligin-neurexin. In contrast to the well-studied neuroligin splice site B, little is known about splice site A. We discovered that inclusion of the positively charged A1 insert in mouse neuroligin-1 increases its binding to heparan sulphate, a modification on neurexin. The A1 insert increases neurexin recruitment, presynaptic differentiation, and synaptic transmission mediated by neuroligin-1. We propose that the A1 insert could be a target for alleviating the consequences of deleterious NLGN1/3 mutations, supported by assays with the autism-linked neuroligin-1-P89L mutant. An enrichment of neuroligin-1 A1 in GABAergic neuron types suggests a role in synchrony of cortical circuits. Altogether, these data reveal an unusual mode by which neuroligin splicing controls synapse development through protein-glycan interaction and identify it as a potential therapeutic target.
Introduction
Synapses are specialized sites of intercellular communication where chemical transmission occurs between neurons in brain circuits. Cell surface trans-synaptic organizing complexes recruit presynaptic vesicles and the neurotransmitter release machinery and apposing postsynaptic receptors and scaffold proteins. Dendritic neuroligins (NLGNs) and their axonal neurexin (NRXN) binding partners form a prototypical synaptic organizing complex (Südhof, 2017). NLGNs bind to two interfaces on NRXN, to the laminin-neurexin-sex hormone (LNS) protein domain and to the heparan sulphate (HS) glycan chain (Zhang et al., 2018). Mutations in all NLGN and NRXN genes are associated with neuropsychiatric disorders. NLGNs and NRXNs are evolutionarily conserved and essential for mouse survival (Missler et al., 2003; Varoqueaux et al., 2006). NLGNs have additional extracellular domain binding partners, cell surface MDGAs, also linked to neuropsychiatric disorders (Connor et al., 2019). MDGA binding to NLGNs occludes the NRXN binding site, thus preventing NLGN-NRXN interaction and suppressing synapse development. Intracellularly, NLGNs can bind to the excitatory postsynaptic scaffold PSD-95 and the inhibitory postsynaptic scaffold gephyrin, interactions that are regulated by phosphorylation (Jeong et al., 2019; Jeong et al., 2017; Letellier et al., 2020; Letellier et al., 2018). NLGN1 functions at excitatory glutamatergic synapses, NLGN2 at inhibitory GABAergic synapses, and NLGN3 at both.
NLGN1 is essential for normal NMDA receptor recruitment, long-term potentiation, and spatial learning and memory (Blundell et al., 2010; Budreck et al., 2013; Jiang et al., 2017; Shipman and Nicoll, 2012). Additional competitive effects of NLGN1 on synapse number were revealed with sparse knockdown (Kwon et al., 2012) and roles in long-term depression revealed in Nlgn1 heterozygous mice (Dang et al., 2018). Copy number, truncating, and missense variants in NLGN1 are associated with autism spectrum disorders (ASD) (Glessner et al., 2009; Nakanishi et al., 2017; O'Roak et al., 2012; Tejada et al., 2019) and obsessive-compulsive disorder (Gazzellone et al., 2016) and NLGN1 polymorphisms are linked to schizophrenia (Chen et al., 2018; Zhang et al., 2015).
NLGNs are regulated by alternative splicing (see Figure 1—figure supplement 1 for gene structures of NLGN1-3). The function of splice site B present only in NLGN1 is well understood. The B insert blocks the interaction of NLGN1 with α-NRXNs, reduces binding to β-NRXNs, and reduces binding to MDGAs (Boucard et al., 2005; Elegheert et al., 2017; Koehnke et al., 2010). The major form of NLGN1 contains this B insert but lacks an insert at splice site A (Chih et al., 2006). Additional forms of NLGN1 and NLGN3 can have conserved A1, A2 or A1A2 splice inserts whereas NLGN2, NLGN4, and NLGN5 can have a single A insert similar to A2 (Bolliger et al., 2008). However, the NLGN A inserts have little effect on interaction with NRXN or MDGA protein domains (Comoletti et al., 2006; Elegheert et al., 2017; Koehnke et al., 2010). At the cellular level, the A2 insert promotes association with GABAergic synapses only in the absence of the B insert (Chih et al., 2006). To the best of our knowledge, a function for the NLGN1 A1 insert has not been reported. Here, we show that the A1 insert increases the binding of NLGN1 to HS, a modification on NRXN, increasing NLGN1 synaptogenic activity. We further report cell type regulation of A1 insertion, identify Rbfox1-3 as potential regulators, and show that A1 insertion can partially restore function of an ASD-linked missense variant of NLGN1.
Results
The NLGN1 A1 insert increases heparin binding
The A1 insert of NLGN1 and NLGN3 forms a positively charged surface, with 9 of the 20 amino acids being arginine or lysine (Figure 1A–C). The two internal cysteine residues form a disulfide bond (Hoffman et al., 2004), contributing to the extended surface. Another constitutive positively charged surface on NLGNs near the dimer interface binds the HS chain of NRXN, an interaction that is necessary along with protein-protein interactions for full NLGN-NRXN complex formation and function (Zhang et al., 2018). We wondered whether the A1 insert with its high density of positively charged surface residues might participate in binding of NLGN to the HS chain of NRXN. To test this idea, we compared relative binding affinity for different splice variants of recombinant purified NLGN1 ectodomain to a heparin column. Indeed, NLGN1 variants containing the A1 insert required higher concentrations of salt than variants lacking A1 for elution from heparin (Figure 1D; all NLGN1 variants expressed in this study contain the B insert). This indicates that A1 insertion increases the affinity of NLGN1 for HS. We further wondered whether the A2 insert with its high acidic composition might counteract the effect of A1 but we observed only a small shift in the peak of elution between NLGN1 +A1 and NLGN1 +A1A2.
The NLGN1 A1 insert enhances neurexin recruitment in coculture
To assess the relative interaction of NLGN1 A splice variants with NRXN, we used a cell-based recruitment assay. NLGN1-expressing non-neuronal cells cocultured with neurons recruit axonal NRXN to contact sites (Zhang et al., 2018). If the observed differences in heparin binding among NLGN splice variants reflect differences in binding to native HS modified NRXN, we expect NLGN1 A1-containing splice variants to recruit more NRXN than NLGN1 variants lacking A1. Indeed, we found that Myc-tagged NLGN1 +A1 and +A1A2 splice forms expressed on COS7 cells cocultured with rat hippocampal neurons recruited more native neuronal NRXN to contact sites than NLGN1 -A or +A2 (Figure 2A–C). We used this cell-based assay to assess NRXN-NLGN1 interaction because recombinant NRXN produced in HEK293 cells is poorly HS modified (Zhang et al., 2018), making it difficult to do direct binding assays with appropriately glycosylated NRXN. Three studies used surface plasmon resonance to assess the effect of NLGN splicing on binding affinity to a truncated NRXN1β ectodomain containing the full LNS domain but lacking the HS modification site. One of these studies using bacterially expressed NRXN1β reported a positive effect of the A1 insert (Comoletti et al., 2006) although two studies using NRXN1β expressed in mammalian cells reported no difference in affinity between NLGN1 -A and NLGN1 +A1 (Elegheert et al., 2017; Koehnke et al., 2010). Altogether, these previous results and our data suggest that the NLGN1 A1 insert does not affect binding to the NRXN LNS domain but increases binding to the NRXN HS modification.
NLGN1 A1 inclusion is high in GABAergic cell types
Our data above show that alternative splicing at the NLGN1 A site affects molecular interactions. Yet, although NLGN1 transcripts containing the A1, A2 and A1A2 inserts have been detected, cell type specific splicing patterns have not been well explored. Thus, we analysed three deep RNA-seq datasets for cell type splicing patterns of the NLGN1 A site. Supplementary file 1 summarizes all RNA-seq datasets analysed in this study. Two datasets for adult mouse cortex from the Allen Institute for Brain Science covered 23,822 single-cell transcriptomes with >100,000 reads per cell detecting approximately 9500 genes per cell (Tasic et al., 2018). Cells were isolated by FACS or manual picking following layer-enriched dissections from many Cre driver lines crossed with reporters for access to select rare cell types, and the resulting 133 transcriptomic cell types were identified by clustering analysis (Tasic et al., 2018). We analysed the primary data (Gene Expression Omnibus (GEO) GSE115746) to assess cell-type splicing at NLGN1 splice site A. In mouse primary visual cortex, NLGN1 A1 inserts were most prevalent in GABAergic cell types, including the well-studied VIP and parvalbumin classes (Figure 3A). Oligodendrocytes also showed high A1 inclusion whereas A1 was essentially absent from NLGN1 in astrocytes and oligodendrocyte precursor cells. Cell type specific splicing patterns were generally similar in anterior lateral motor cortex (Figure 3B) except here the Meis2-expressing divergent GABAergic neuron class showed more NLGN1 A1 inclusion. We further analysed an independent dataset of ribosome-engaged transcripts from genetically defined neuron types in mouse cortex and hippocampus (Furlanis et al., 2019). Their deep RNA-seq designed to study splice isoforms covered >100 million reads per biological replicate, detecting >12,000 genes per sample with full-length coverage across transcripts. In this dataset of actively translated transcripts (GEO GSE133291), we again found that NLGN1 A1 inclusion was highest in GABAergic neurons of the cortex, including VIP and parvalbumin classes (Figure 3C).
To determine whether NLGN1 A1 inclusion changes with development, we assessed two deep RNA-seq datasets from mouse cortex spanning from embryonic day (E)14.5 to 2 years (Lister et al., 2013; Yan et al., 2015; Supplementary file 1). Previous analysis demonstrated dynamic splicing regulation of cassette exons in embryonic and postnatal cortex up to one month old (Weyn-Vanhentenryck et al., 2018). We estimated the abundance of NLGN1 isoforms by a regression analysis using reads mapped to exon junctions of the alternatively spliced region. Developmentally, NLGN1 A1 inclusion in mouse cortex peaked during the first to second postnatal weeks (Figure 4A,B).
NLGN1 A1 inclusion is regulated by Rbfox
Cell-type specific alternative splicing is controlled by RNA-binding proteins that recognize specific regulatory sequences embedded in the pre-mRNA transcripts. Splicing factors specifically expressed or enriched in neurons include Rbfox, Mbnl, and Ptbp2 which have all been demonstrated to regulate alternative splicing of numerous neuronal transcripts (Raj and Blencowe, 2015; Vuong et al., 2016). Thus, we determined whether genetic knockout (KO) of these families of splicing factors altered splicing of NLGN1 A1.
The three Rbfox family members are thought to have considerable functional redundancy as they all bind to the same RNA sequence motif and have overlapping expression patterns in neurons (Vuong et al., 2016). To assess their combined role in NLGN1 A site splicing, due to limitations with lethality in vivo, we studied triple KO of Rbfox1, Rbfox2 and Rbfox3 in spinal neurons differentiated from mouse embryonic stem cells (Jacko et al., 2018; Supplementary file 1). At 5 days in culture, the embryonic stem cell-derived neurons elaborate branched processes and fire trains of action potentials upon current injection. Over the next 5 days of maturation, they show splicing changes paralleling those of early postnatal mouse cortex (Jacko et al., 2018). Our analyses of this dataset revealed that Rbfox triple KO effectively eliminated NLGN1 A1 inclusion at both stages of neuron maturation (Figure 4C).
To identify additional RNA binding proteins which might regulate NLGN1 splicing, we similarly examined published RNA-seq data derived upon depletion of individual RNA binding proteins (Supplementary file 1). The data were derived from: adult hippocampus of Mbnl2 KO mice (Charizanis et al., 2012); adult frontal cortex of Mbnl1−/−Mbnl2loxP/loxP Nestin-Cre nervous system-specific double KO mice (Weyn-Vanhentenryck et al., 2018); embryonic day 18 brains of Ptbp2loxP/loxP Nestin-Cre nervous system-specific KO mice, and postnatal day 1 cortex of Ptbp2loxP/loxP Emx1-Cre forebrain glutamatergic neuron-selective KO mice (Li et al., 2014). These datasets were analysed for alternative splicing in our previous study (Weyn-Vanhentenryck et al., 2018), from which we obtained reads mapped to the alternatively spliced region of NLGN1 to estimate abundance of different splice variants. Our analyses of these datasets essentially rules out a role for Mbnl in NLGN1 A site splicing (Figure 4D). For Ptbp2, the Emx1-Cre KO datasets did not show any difference in NLGN1 A1 splicing, but NLGN1 A1 inclusion was reduced in the Nestin-Cre KO dataset (Figure 4E). These findings suggest Ptbp2 may regulate NLGN1 -A1 splicing in neurons outside the forebrain. Therefore, our transcriptomic analyses indicated a major role for Rbfox and lesser roles, if any, for Mbnl or Ptbp2 in NLGN1 A1 splicing.
The NLGN1 A1 insert enhances presynaptic differentiation in coculture
To test the functional impact of the NLGN1 A1 splice site, we first used the neuron - COS7 cell coculture assay to assess synaptogenic activity of the NLGN1 splice variants. Via NRXN recruitment as seen in Figure 2, NLGNs expressed on the surface of non-neuronal cells induce full presynaptic differentiation in contacting axons, reflected by clustering of multiple presynaptic components (Scheiffele et al., 2000). NLGN binding to axonal NRXN is required for this synaptogenic activity in coculture, based on loss of activity upon NRXN triple knockdown (Gokce and Südhof, 2013; Zhang et al., 2018) or by NLGN point mutations that disrupt binding to the NRXN LNS domain (Ko et al., 2009) or to the NRXN HS modification (Zhang et al., 2018). Here we found that NLGN1 +A1 and +A1A2 induced greater presynaptic differentiation than other splice variants, assessed by synapsin clustering at axon - COS7 cell contact sites lacking dendrite contact to exclude native synapses (Figure 5). Thus, the NLGN1 -A1 insert promotes presynaptic differentiation in coculture assays.
The NLGN1 A1 insert promotes structural and functional synapse development
To assess the role of the NLGN1 A1 insert at native synapses, we used a molecular replacement strategy knocking down native NLGN1 with shNlgn1 (Zhang et al., 2018) and re-expressing RNAi-resistant Myc-NLGN1* lacking or containing the A1 insert. For these assays, we focused on NLGN1 -A, the major neuronal form (Figures 3 and 4; Chih et al., 2006), and NLGN1 +A1. We found that NLGN1* +A1 induced greater presynaptic differentiation than NLGN1* -A, assessed by total intensity of vesicular glutamate transport VGlut1 clustering onto expressing neurons (Figure 6A–D). There was no difference between the NLGN1 isoforms in the density of VGlut1 clusters per dendrite area, suggesting no difference in synapse numbers, but a difference in total intensity of VGlut1 per cluster.
We observed no difference in the localization of Myc-NLGN1* -A and +A1 in these assays. However, as in previous assays expressing YFP-NLGN1 in the absence of recombinant postsynaptic scaffolds (Graf et al., 2004), both isoforms of Myc-NLGN1* showed high diffuse levels with poor postsynaptic clustering. Thus, to determine whether A1 alternative splicing mediates differential synaptic recruitment, we used a more sensitive tag on NLGN1* and slightly different culture conditions (Chamma et al., 2016; Letellier et al., 2018). NLGN1* was tagged with an extracellular 15-amino-acid acceptor peptide (AP) that is biotinylated upon co-expression of a biotinylating enzyme BirAER and then surface labelled with fluorescent streptavidin. The longer culture time and co-expression of Homer1c-dsRed to mark postsynaptic sites may also enhance synapse maturation (Zeng et al., 2018), altogether resulting in postsynaptic clustering of AP-NLGN1*. However, there was no difference in the degree of synaptic enrichment of AP-NLGN1* -A versus +A1, nor in Homer1c-dsRed synaptic enrichment, cluster density, or cluster area between groups (Figure 6E–I). Collectively, our data indicate that the NLGN1 A1 splice insert mediates differential recruitment of NRXN and presynaptic differentiation but not differential postsynaptic targeting.
To assess effects of NLGN1 A1 splicing directly on synaptic function, we used a similar molecular replacement strategy to knockdown native NLGN1 and re-express NLGN1* -A or +A1 and recorded miniature excitatory synaptic currents (mEPSCs) in cultured hippocampal neurons. Neurons expressing shNlgn1 and rescued with NLGN1* +A1 had significantly greater mEPSC frequency than those rescued with NLGN1* -A, with a corresponding reduction in mEPSC interevent interval (Figure 7). There was no difference between groups in mEPSC amplitude. Thus, the NLGN1 A1 splice insert enhances functional transmission as well as structural presynaptic differentiation.
A1 insertion partially restores autism-linked NLGN1 P89L synaptogenic function
We propose that the A1 insert might be a potential target for alleviating deficits of ASD NLGN1 missense mutations by enhancing their function. To test this idea, we chose the NLGN1 P89L missense variant found in two ASD siblings but not in controls (Nakanishi et al., 2017). Modelling in Nlgn1 P89L heterozygous knock-in mice resulted in reduced NLGN1 protein levels and deficits in social interaction, altered social dominance, and impaired spatial memory, supporting a causative role of this mutation in autism (Nakanishi et al., 2017). We confirmed an expected reduction in surface expression of Myc-NLGN1 -A P89L relative to WT (Figure 8—figure supplement 1), likely reflecting enhanced endoplasmic reticulum-associated degradation (Nakanishi et al., 2017).
We next assessed the synaptogenic activity of NLGN1 P89L. Interestingly, even though cells with equal NLGN1 surface expression were chosen for the coculture assay, the P89L mutation significantly reduced presynaptic differentiation by NLGN1 (Figure 8). NLGN1 P89L -A induced <20% of the level of synapsin clustering as wild type NLGN1 -A, even after controlling for any difference in surface expression. Thus, the P89L mutation not only reduces total and surface levels of NLGN1 (Nakanishi et al., 2017; Figure 8—figure supplement 1) but also renders the NLGN1 that reaches the cell surface less effective at inducing presynaptic differentiation.
Importantly, addition of the A1 insert partially alleviated this deficit: NLGN1 P89L +A1 induced greater presynaptic differentiation than NLGN1 P89L -A (Figure 8). Furthermore, in the native synapse molecular replacement assay with NLGN1 knockdown, the total fluorescence intensity of VGlut1 inputs was higher onto hippocampal neurons expressing NLGN1* P89L +A1 than NLGN1* P89L -A (Figure 9). Thus, the A1 insert functions in the context of the P89L ASD mutation to enhance presynaptic differentiation.
Discussion
In contrast to the well-studied NLGN1 B splice site, the A splice site has been poorly studied, with information previously lacking on the A1 insert. Yet the A1 insert appears highly conserved among vertebrates, including humans, mice, zebrafish, and chickens (Figure 1A; Rissone et al., 2010; Wahlin et al., 2010), suggesting a functional importance. We show here that the A1 insert increases binding of NLGN1 to heparin and increases recruitment of the axonal binding partner of NLGN1, HS-modified NRXN. It will be important in future studies to directly compare the affinities of purified NLGN1 splice forms with native HS-modified NRXN, such as with a neuron-based binding assay. Our data reveal an intersection between two forms of post-transcriptional modification, alternative splicing of NLGN1 and glycan modification of NRXN. Functionally, NLGN1 A1 inclusion increases presynaptic differentiation and synaptic transmission but does not affect NLGN1 synaptic targeting or synapse density. Data from KO neurons reveals regulation of A1 splicing by the Rbfox family of splicing factors, and transcriptomic analyses reveals high A1 inclusion in multiple cortical GABAergic cell types. Finally, we show that A1 inclusion enhances function not just of wild type NLGN1 but also of the ASD-linked NLGN1 P89L mutant. We suggest that the A splice site might be harnessed as a means to restore function in disorders involving deleterious mutations in NLGN1, and potentially NLGN3, by developing therapeutics to convert the more prevalent -A form to the more synaptogenic +A1 form.
The role identified here for the NLGN1 splice site A1 insert is an unusual one, increasing NLGN1 interaction with HS glycan and thus enhancing synaptogenic function. Although there are many cases of alternative splicing regulating synapse development through altered protein-protein interactions, a mechanism involving altered protein-glycan interaction is less common. The NLGN1 B splice site also regulates synaptogenic function partially through glycosylation, in that case through N-glycosylation of the NLGN1 B insert blocking binding to α-NRXN while retaining binding to β-NRXN (Boucard et al., 2005). Neural-specific alternative splicing of agrin at its y site also regulates its interaction with HS, and HS binding reduces agrin interaction with dystroglycan (Gesemann et al., 1996; O'Toole et al., 1996). However, the y site and these interactions are not critical for agrin synaptogenic activity (Burgess et al., 1999; Li et al., 2018), unlike the central role of the NRXN interaction for NLGN1 function.
Our data reveal effects of the NLGN1 A1 insert on increasing NRXN recruitment and presynaptic differentiation in coculture, and on increasing VGlut1 levels at inputs and mEPSC frequency in hippocampal neurons. However, the NLGN1 A1 insert had no apparent effect on the synaptic targeting of NLGN1. This finding is consistent with other data suggesting that the excitatory postsynaptic localization of NLGN1 is largely controlled by intracellular interactions regulated by multiple kinases (Jeong et al., 2019; Jeong et al., 2017; Letellier et al., 2020; Letellier et al., 2018). The NLGN1 +A1-associated increase in mEPSC frequency and VGlut1 cluster intensity without a change in VGlut1 or Homer1c-dsRed cluster density suggest there is no change in synapse numbers but rather an increase in neurotransmitter release. These findings are consistent with previous reports of a retrograde effect of NLGN1 on neurotransmitter release probability (Futai et al., 2007; Stan et al., 2010). In contrast, the lack of effect of the NLGN1 A1 insert on mEPSC amplitude suggests no effect on postsynaptic sensitivity. Thus, altogether our data are consistent with a purely retrograde mechanism of action of the NLGN1 A1 insert through enhanced NRXN recruitment mediating enhanced presynaptic differentiation and increased transmitter release rate. While this work was under revision, it was reported that the A1 insert in NLGN3 regulates GABAergic transmission, as overexpression of NLGN3 +A1 or +A1A2 reduced GABAergic transmission whereas NLGN3 -A or +A2 increased GABAergic transmission relative to neighbour untransfected cells in hippocampal slice cultures (Uchigashima et al., 2020). Differential effects were also found on presynaptic release probability. We suggest that the mechanism of this effect may also involve differential interactions with NRXN -HS.
The effect of the higher NLGN1 A1 inclusion in GABAergic than in glutamatergic neuron classes may be to increase excitatory input selectively onto the GABAergic neurons, thus enhancing synchrony of the overall network. In particular, cortical VIP and parvalbumin interneurons, which showed high NLGN1 A1 inclusion in all datasets, play key roles in neural synchrony and cognitive processing. For example, VIP interneuron disinhibition of prefrontal responses to hippocampal inputs controls avoidance behaviour (Lee et al., 2019). NLGN3 on parvalbumin interneurons contributes to gamma oscillations and social behaviour as well as fear conditioning (Cao et al., 2018; Polepalli et al., 2017).
Our data also shed some light on the mechanisms regulating alternative splicing of NLGN1 A1, with KO data supporting a role for Rbfox and a possible lesser role for Ptbp2 splice factors. Although further validation of NLGN1 as an Rbfox target will be needed, NLGN1 appears to be one among many Rbfox targets. Unlike the highly dedicated splicing program of SLM2 regulating synaptic properties through NRXN site 4 splicing (Traunmüller et al., 2016), the Rbfox family regulates a broader range of targets controlling synaptic properties and other aspects of neuronal maturation including axon initial segment assembly (Jacko et al., 2018). Rbfox proteins also act as more than just splicing factors; in GABAergic neurons, a mechanism involving Rbfox1 binding to the Vamp1 mRNA 3' UTR regulates synaptic transmission (Vuong et al., 2018). Like NLGNs, RBFOX1 is a risk gene for ASD based on strong evidence including de novo copy number deletions (Sebat et al., 2007; Zhao, 2013).
The results here with the P89L NLGN1 mutant support the idea that elevating A1 insertion is a promising direction to enhance the function of NLGN1 in cases of deleterious mutations. This approach will likely extend to NLGN3 as well as NLGN1, given their high sequence homology including the A1 insert (Figure 1A). NLGN3 is among the top risk genes for ASD with multiple functionally deleterious missense mutations (Jamain et al., 2003; Quartier et al., 2019). In the majority of cases which involve heterozygous mutations, reagents that increase A1 insertion could act by enhancing function of both the mutant NLGN and the wild type allele. NRXN1 is also among the top risk genes for ASD as well as for schizophrenia and Tourette’s Syndrome (Tourette Syndrome Association International Consortium for Genetics (TSAICG) et al., 2017; Rees et al., 2014; Südhof, 2017). Therapies targeting wild type NLGN splicing to elevate the function of NLGN-NRXN complexes may also be partially efficacious in cases of NRXN mutations. Clinically effective oligonucleotide reagents targeting splicing events have reached the bedside for other disorders, notably for increasing specific exon inclusion in SMN2 to treat spinal muscular atrophy (Bennett et al., 2019; Singh et al., 2017).
Materials and methods
DNA constructs
Request a detailed protocolMouse NLGN1(-A+B) (GenBank: XM_017319496) was cloned from adult mouse whole brain by RT-PCR. Insert A1 (GenBank: XM_017319494.1) and A1A2 (GenBank: XM_006535415.2) were inserted by site-directed mutagenesis. NLGN1(+A2+B) was a gift from Peter Scheiffele (Scheiffele et al., 2000). To construct the P89L mutant, nucleotides CCA (Pro) were changed to CTA (Leu). A Myc tag and linker (EQKLISEEDLGGQ) were inserted between amino acid Gln46 and Lys47. CFP-linker-P2A (YGSGATNFSLLKQAGDVEENPGP) was fused at the N-terminus of Myc-NLGN1 before the signal sequence. For the heparin binding assay, since pcDNA4-HA-ecto-NLGN1 (Zhang et al., 2018) is the NLGN1(+A2) isoform, the A2 region was removed to construct NLGN1(-A) or replaced with insert A1 or A1A2 for the NLGN1(+A1) or NLGN1(+A1A2) isoform, respectively, to express the NLGN1 ectodomain of each isoform. For coculture assays, Myc-NLGN1 isoforms and CFP-P2A-Myc-NLGN1(-A) WT and P89L mutant were inserted into pCAGGS under a CAG promotor to express in COS7 cells. To construct Myc-Amigo, NLGN1 was replaced with rat Amigo (amino acid 28–493) from Amigo-CFP (Siddiqui et al., 2010; Zhang et al., 2018). To construct Myc-CD4, the HA tag in HA-CD4 (Takahashi et al., 2011) was replaced with the Myc tag. For co-expression of Myc-NLGN1 and CFP in COS7 cells, pECFP-N1 (Clontech) was used. For VGlut1 recruitment assays, Myc-NLGN1 isoforms and CFP-P2A-Myc-NLGN1 (-A) and (+A1) P89L mutant were inserted into pLL3.7 under a synapsin promoter to express in hippocampal neurons. For electrophysiology, NLGN1(-A) and NLGN1(+A1) isoforms were made from pFB-hSyn-DIO-YFP-P2A-HA-NLGN1, which is the NLGN1(+A2) isoform (Zhang et al., 2018). The A2 region was removed for the NLGN1 (-A) isoform or replaced with A1 to construct the NLGN1(+A1) isoform. pCAG-Cre was described previously (Zhang et al., 2018). To knock-down endogenous NLGN1, for most experiments pLL3.7U6-shNlgn1-hSyn-CFP was used which was generated from pLL3.7U6-shNlgn1-hSyn-YFP and the shRNA resistant form NLGN1* made by mutating the underlined nucleotides 5’-CAAGGGGAAGGGTTGAAGTT-3’ to 5’-CAAGGCGAGGGACTAAAGTT-3’ as previously reported (Zhang et al., 2018). For the synaptic enrichment assay, the plasmids for shNlgn1-GFP, RNAi-resistant AP-NLGN1*(+A2+B), BirAER, and dsRed-Homer1c were previously described, with thanks to Alice Ting (Chamma et al., 2016; Howarth et al., 2006; Mondin et al., 2011). AP-NLGN1*(-A) and (+A1) were generated from the (+A2) form by In-Fusion HD Cloning (Takara Bio) or site-directed mutagenesis.
Cell culture and transfection
Request a detailed protocolThis study was performed in accordance with the recommendations of the Canadian Council on Animal Care. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (A16-0086 and A16-0090) of the University of British Columbia. For most experiments, primary hippocampal neurons were prepared from male and female rat embryos at embryonic day 18 as previously reported (Kaech and Banker, 2006; Zhang et al., 2018). The dissociated hippocampal neurons were plated on 18 mm round coverslips coated with poly-L-lysine at the density of 36,000 neurons/coverslip. The coverslips were flipped over and neurons grown suspended above a glial feeder layer in a 60 mm dish. To block glia cell proliferation, cytosine arabinoside at a final concentration of 5 mM was added at day in vitro (DIV) 1. Neurons were transfected with 2 μg of plasmid DNA and 2 μl of Lipofectamine 2000 (Thermo Fisher Scientific) at DIV 5. The following are the combinations of plasmids used for each assay with ratio 10:8:2: for VGlut1 immunofluorescence, U6-shNlgn1-hSyn-CFP + hSyn-Myc-NLGN1* WT + pLL(syn)-MCS (empty vector) or U6-shNlgn1-hSyn-YFP + hSyn-CFP-P2A-Myc-NLGN1* P89L + pLL(syn)-MCS (empty vector); for electrophysiology, U6-shNlgn1-hSyn-YFP + hSyn-DIO-YFP-P2A-HA-NLGN1* (-A) or (+A1) + pCAG-Cre.
For the synaptic enrichment assay, dissociated rat hippocampal neurons were electroporated with the Amaxa system (Lonza) using 300,000 cells per cuvette with the following combination of plasmids: shNlgn1-GFP (3 μg), BirAER (1 μg), Homer1c-dsRed (1 μg), and AP-NLGN1* (-A) or (+A1) (1 μg). Electroporated neurons were immediately resuspended in Minimal Essential Medium supplemented with 10% horse serum and plated on 18 mm coverslips previously coated with poly-L-lysine. Three hours after plating, coverslips were flipped onto 60 mm dishes containing a glial cell feeder layer in Neurobasal Plus Medium supplemented with NeuroCult SM1 Neuronal supplement (STEMCELL Technologies), and cultured for 2 weeks before experiments.
Mycoplasma-negative COS7 cells or HEK239T cells obtained from ATCC without further authentication were maintained in Dulbecco’s Modified Eagle’s medium (Thermo Fisher Scientific) with 10% bovine growth serum. For transfection, plasmid DNA and 0.045% Polyethylenimine (Sigma 408727) were mixed in a 1:3 or 1:4 ratio (w/v). For coculture assays, an N-methyl-D-aspartate (NMDA) receptor inhibitor, APV, at a final concentration of 100 μM was added into the neuron dishes at DIV 6, 9, and 13. COS7 cells were trypsinized 24 hr after transfection. 40,000 COS7 cells were seeded on a coverslip with neurons at DIV 13. After 1 hr, the coverslip was flipped back into a glia dish and 24 hr later, the COS7-neuron cocultures were fixed.
Immunocytochemistry
Request a detailed protocolFor coculture assays, neurons and COS7 cells were fixed with 4% formaldehyde/4% sucrose/PBS, pH 7.4 for 12 min, blocked with 10% BSA/PBS for 30 min at 37°C, and incubated with Myc antibody in 3% BSA/5% normal goat serum (NGS)/PBS for surface staining overnight at 4°C. The next day, the cells were fixed again for 5 min, permeabilized with 0.2% Triton X-100/PBS, blocked with 10% BSA, and incubated with the primary antibodies in 3% BSA/5% NGS/PBS overnight at 4°C. Cells were then incubated with the secondary antibodies in 3% BSA/5% NGS/PBS for 45 min at 37°C. The coverslips were mounted in elvanol (Tris-HCl, glycerol, and polyvinyl alcohol, with 2% 1,4-diazabicyclo{2,2,2} octane). For surface expression of Myc-NLGN1(-A) WT and P89L in COS7 cells, cells were fixed and blocked as above 48 hr after transfection, followed by incubation with Myc antibody overnight at 4°C, and incubation with the secondary antibody the next day. For VGlut1 immunofluorescence assays, the transfected hippocampal neurons were fixed at DIV 12 and immunostained as above, except the second 5 min fixation was not done. The following primary antibodies were used: Rabbit polyclonal Myc antibody (Sigma C3956; 1:40000), rabbit polyclonal pan-NRXN antibody (Millipore ABN161; 1:1000), chicken polyclonal MAP2 antibody (Abcam ab5392; 1:80000), mouse monoclonal VGlut1 antibody (NeuroMab 75–066; clone N28/9; IgG1; 1:4000), mouse monoclonal SynapsinI antibody (Synaptic Systems 106 011; clone 46.1; IgG1; 1:20000), mouse monoclonal Tau antibody (Millipore MAB3420; clone PC1C6; IgG2a; 1:2000). Secondary antibodies coupled to Alexa Flour 488, 568, 647 (Thermo Fisher Scientific; 1: 1000) and anti-chicken IgY AMCA (Jackson ImmunoResearch 703-155-155; 1:400) were used. Image acquisition and analysis was performed blind to the experimental condition. Images were acquired on a Zeiss Axioplan 2 microscope with 63x/1.4 numerical aperture (NA) oil objective, ORCA-Flash4.0 FL CMOS camera (Hamamatsu) and custom filter sets or a Zeiss LSM700 with 40x/1.4 NA oil objective, ORCA-Flash4.0 CMOS camera (Hamamatsu) and custom filter sets. The acquired images were analysed with Fiji. Off-cell background was subtracted from each value. COS7 cells or neurons were selected for analysis based only on cell health and cell surface expression level of Myc-NLGN1, except for Figure 8—figure supplement 1 where cells were chosen based on CFP expression. For the coculture assays, the total intensity of pan-NRXN or Synapsin puncta was measured within the area of COS7 cells where Tau-positive axon was present and MAP2-positive dendrite was absent. For the neuron cultures, the number and total intensity of VGlut1 puncta was measured and normalized to the area or length of MAP2-positive dendrite.
For the synaptic enrichment assay, for NLGN1 staining, cell cultures were rinsed twice in pre-warmed Tyrode solution (15 mM D-glucose, 108 mM NaCl, 5 mM KCl, 2 mM MgCl2, 2 mM CaCl2 and 25 mM HEPES, pH 7.4, 280 mOsm). Cells were then incubated for 10 min at 37°C with Tyrode solution containing 1% biotin-free Bovine Serum Albumin (Roth, ref 0163.4), followed by an incubation in 100 nM Alexa 647-conjugated streptavidin (cat#S32357, Thermo Fisher Scientific). Following two washes in Tyrode solution, cells were imaged on an inverted epifluorescence microscope (Nikon Eclipse TiE) equipped with a 60x/1.49 NA objective lens and an sCMOS camera (Prime 95B, Photometrics) driven by the Metamorph software (Molecular Devices). Homer1c-DsRed puncta were thresholded using Metamorph, and the number of puncta per dendrite length was determined, as well as area and intensity relative to dendrite shaft. Regions around Homer1c-DsRed objects were created and transferred to the streptavidin image. The intensity of the streptavidin signal in the puncta was normalized to the shaft signal, giving the NLGN1 synaptic enrichment.
Heparin binding assay
Request a detailed protocolPurification of NLGN1 ectodomain proteins and the heparin binding assay were previously described (Zhang et al., 2018). Briefly, an N-terminal HA tagged and C-terminal His tagged NLGN1 ectodomain of each isoform was transiently expressed in HEK293T cells and purified with Ni-NTA agarose beads (QIAGEN). Purified NLGN1 ectodomains were incubated with heparin agarose (GE Healthcare) and eluted with NaCl in step-wise gradient concentrations (50 mM – 3 M) in 20 mM HEPES, pH 7.4. Collected eluates were analysed by immunoblotting with rat monoclonal HA antibody (Roche 11867431001; clone 3F10; 1:2000), secondary HRP-conjugated antibody, and detected using the SuperSignal Chemiluminescent kit (Thermo Fisher Scientific).
Electrophysiology
Request a detailed protocolCultured hippocampal neurons (DIV 13–14) were transferred to a submerged chamber and continuously perfused (2–3 ml/min) with (in mM): 140 NaCl, 5.4 KCl, 1.25, 1 MgCl2, 1.3 CaCl2, 10 HEPES and 3.6 D-glucose with pH adjusted to 7.35 using NaOH. All chemicals and drugs were purchased from Sigma or BioShop, Canada unless otherwise stated. YFP transfected neurons were identified with a microscope equipped with fluorescent and phase contrast optics. All recordings were performed at room temperature with a MultiClamp 700B amplifier. Cells were voltage clamped at −60 mV. Recording of mEPSCs was conducted using pipettes filled with an intracellular solution containing (in mM): 122.5 Cs-methanesulfonate, 17.5 CsCl, 2 MgCl2, 10 EGTA, 10 HEPES, 4 ATP (K), and 5 QX-314, with pH adjusted to 7.2 by CsOH. Tetrodotoxin (500 nM; Abcam) and bicuculline methiodide (10 μM; Abcam) were added to perfused saline to block action potentials and GABA receptor-mediated inhibitory synaptic currents, respectively. mEPSCs were recorded using WinLTP software in continuous acquisition mode. Analyses for frequency and amplitude were conducted using MiniAnalysis software.
Analysis of RNA-seq data and quantification of NLGN1 isoform abundance
Request a detailed protocolAll RNA-seq datasets analysed in this work, including a brief description of samples, read length, sequencing depth, and accession numbers are summarized in Supplementary file 1. In particular, neuronal cell type-specific splicing of NLGN1 was analysed using single cell RNA-seq data of adult mouse cortex, which is composed of ~25,000 cells of diverse neuronal cell types from primary visual cortex (VISp) and anterior lateral motor cortex (ALM) (Tasic et al., 2018). In our analysis, we used ~21000 core cells unambiguously assigned to specific neuronal cell types defined by transcriptional profiles in the original study. In addition, we also examined NLGN1 splicing in major glutamatergic and GABAergic neuronal cell types in the cortex and hippocampus derived by translational profiling (Furlanis et al., 2019). For each of these datasets, RNA-seq reads were mapped by OLego v1.1.2 (Wu et al., 2013) to the reference genome (mm10) and a comprehensive database of exon junctions was provided for read mapping. Only reads unambiguously mapped to the genome or exon junctions (single hits) were used for downstream analysis. RNA-seq data for cortical development and RNA-binding protein depletion were processed and analysed previously (Jacko et al., 2018; Weyn-Vanhentenryck et al., 2018; Yan et al., 2015) and the number of reads mapped to each exon and exon junctions derived from the original analysis was used to quantify NLGN1 isoforms.
To estimate the abundance of NLGN1 isoforms, we first extracted the number of reads covering each of the six exon junctions connecting the alternatively spliced A1 and A2 exons and their flanking constitutive exons. The read counts from replicates in bulk data or from single cells assigned to the same cell types in the single cell RNA-seq data were pooled together. The read count of the six junctions were then taken as input to estimate the fraction of the four NLGN1 splice isoforms including A1A2, A1, A2 and –A using least squares estimation with the R function lsfit.
Statistical analysis
Request a detailed protocolStatistical analysis was performed using Microsoft Excel, GraphPad Prism, GraphPad InStat, and SigmaPlot. Statistical details are provided in the Figure legends. For most experiments, data did not pass the D’Agostino and Pearson test for normality so comparisons were made using the Mann-Whitney test or Kruskal-Wallis test with post hoc Dunn's multiple comparisons tests, as indicated. For the VGlut1 analysis, an outlier was removed using an aggressive Grubbs’ method α = 0.0001 in GraphPad Prism. All data are reported as the mean ± standard error of the mean (SEM).
Data availability
All data generated during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2, 5 and 8.
-
NCBI Gene Expression OmnibusID GSE115746. Shared and distinct transcriptomic cell types across neocortical areas.
-
NCBI Gene Expression OmnibusID GSE133291. Landscape of ribosome-engaged transcript isoforms reveals extensive neuronal-cell-class-specific alternative splicing programs.
-
NCBI Gene Expression OmnibusID GSE38497. Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy.
-
NCBI Gene Expression OmnibusID GSE47966. Global epigenomic reconfiguration during mammalian brain development.
-
NCBI Sequence Read ArchiveID SRP055008. Systematic discovery of regulated and conserved alternative exons in the mammalian brain reveals NMD modulating chromatin regulators.
-
NCBI Gene Expression OmnibusID 51733. The splicing regulator PTBP2 controls a program of embryonic splicing required for neuronal maturation.
-
NCBI Sequence Read ArchiveID SRP142522. Precise temporal regulation of alternative splicing during neural development.
-
NCBI Sequence Read ArchiveID SRP128054. Rbfox Splicing Factors Promote Neuronal Maturation and Axon Initial Segment Assembly.
References
-
Antisense oligonucleotide therapies for neurodegenerative diseasesAnnual Review of Neuroscience 42:385–406.https://doi.org/10.1146/annurev-neuro-070918-050501
-
Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behaviorJournal of Neuroscience 30:2115–2129.https://doi.org/10.1523/JNEUROSCI.4517-09.2010
-
Pumping the brakes: suppression of synapse development by MDGA-neuroligin interactionsCurrent Opinion in Neurobiology 57:71–80.https://doi.org/10.1016/j.conb.2019.01.002
-
Regulation of hippocampal long term depression by neuroligin 1Neuropharmacology 143:205–216.https://doi.org/10.1016/j.neuropharm.2018.09.035
-
Uncovering obsessive-compulsive disorder risk genes in a pediatric cohort by high-resolution analysis of copy number variationJournal of Neurodevelopmental Disorders 8:36.https://doi.org/10.1186/s11689-016-9170-9
-
Membrane-tethered monomeric neurexin LNS-domain triggers synapse formationJournal of Neuroscience 33:14617–14628.https://doi.org/10.1523/JNEUROSCI.1232-13.2013
-
Posttranslational modifications of neuroligins regulate neuronal and glial signalingCurrent Opinion in Neurobiology 45:130–138.https://doi.org/10.1016/j.conb.2017.05.017
-
Neuroligin-1-dependent competition regulates cortical synaptogenesis and synapse numberNature Neuroscience 15:1667–1674.https://doi.org/10.1038/nn.3256
-
Neuromuscular junction formation, aging, and disordersAnnual Review of Physiology 80:159–188.https://doi.org/10.1146/annurev-physiol-022516-034255
-
Neurexin-neuroligin adhesions capture surface-diffusing AMPA receptors through PSD-95 scaffoldsJournal of Neuroscience 31:13500–13515.https://doi.org/10.1523/JNEUROSCI.6439-10.2011
-
Analysis of copy number variations at 15 schizophrenia-associated lociBritish Journal of Psychiatry 204:108–114.https://doi.org/10.1192/bjp.bp.113.131052
-
Characterization of the neuroligin gene family expression and evolution in zebrafishDevelopmental Dynamics 239:688–702.https://doi.org/10.1002/dvdy.22196
-
Neuroligin3 splice isoforms shape inhibitory synaptic function in the mouse HippocampusJournal of Biological Chemistry 295:8589–8595.https://doi.org/10.1074/jbc.AC120.012571
-
The neurogenetics of alternative splicingNature Reviews Neuroscience 17:265–281.https://doi.org/10.1038/nrn.2016.27
-
Alternative splicing of neuroligin and its protein distribution in the outer plexiform layer of the chicken retinaThe Journal of Comparative Neurology 518:4938–4962.https://doi.org/10.1002/cne.22499
-
OLego: fast and sensitive mapping of spliced mRNA-Seq reads using small seedsNucleic Acids Research 41:5149–5163.https://doi.org/10.1093/nar/gkt216
Article and author information
Author details
Funding
Simons Foundation (SFARI 608066)
- Ann Marie Craig
Canadian Institutes of Health Research (FDN-143206)
- Ann Marie Craig
National Institutes of Health (R01NS089676)
- Chaolin Zhang
National Institutes of Health (R01GM124486)
- Chaolin Zhang
Agence Nationale de la Recherche (grant « Synthesyn » ANR-17-CE16-0028-01)
- Olivier Thoumine
Fondation pour la Recherche Médicale (« Equipe FRM » DEQ20160334916)
- Olivier Thoumine
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
We thank Xiling Zhou and Anny Chih for assistance with neuron cultures and fluorescence measures. This work was supported by Canadian Institutes of Health Research FDN-143206 and Simons Foundation Autism Research Initiative SFARI 608066 grants to AMC, National Institutes of Health R01NS089676 and R01GM124486 grants to CZ, and Agence Nationale pour la Recherche (grant « Synthesyn » ANR-17-CE16-0028-01) and Fondation pour la Recherche Médicale (« Equipe FRM » DEQ20160334916) to OT.
Ethics
Animal experimentation: This study was performed in accordance with the recommendations of the Canadian Council on Animal Care. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (A16-0086 and A16-0090) of the University of British Columbia.
Copyright
© 2020, Oku et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,620
- views
-
- 238
- downloads
-
- 10
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Developmental Biology
Cells called alveolar myofibroblasts, which have a central role in the development of the lung after birth, receive an orchestrated input from a range of different signaling pathways.
-
- Developmental Biology
We have generated single cell transcriptomic atlases of vomeronasal organs (VNO) from juvenile and adult mice. Combined with spatial molecular imaging, we uncover a distinct, previously unidentified class of cells that express the vomeronasal receptors (VRs) and a population of canonical olfactory sensory neurons in the VNO. High-resolution trajectory and cluster analyses reveal the lineage relationship, spatial distribution of cell types, and a putative cascade of molecular events that specify the V1r, V2r, and OR lineages from a common stem cell population. The expression of vomeronasal and olfactory receptors follow power law distributions, but there is high variability in average expression levels between individual receptor and cell types. Substantial co-expression is found between receptors across clades, from different classes, and between olfactory and VRs, with nearly half from pairs located on the same chromosome. Interestingly, the expression of V2r, but not V1r, genes is associated with various transcription factors, suggesting distinct mechanisms of receptor choice associated with the two cell types. We identify association between transcription factors, surface axon guidance molecules, and individual VRs, thereby uncovering a molecular code that guides the specification of the vomeronasal circuitry. Our study provides a wealth of data on the development and organization of the accessory olfactory system at both cellular and molecular levels to enable a deeper understanding of vomeronasal system function.